1. HOME
2. Research Insight
3. Clinical Trial Imaging Market Size & Share - Global Future Growth Expectations

The global clinical trial imaging market is projected to reach USD 1.9 billion by 2028 from USD 1.3 billion in 2023, at a CAGR of 7.8% during the forecast period. The expansion of the clinical trial imaging market is primarily propelled by factors like heightened expenditure on research and development, the upsurge in the pharmaceutical and biotechnology sector, and the proliferation of Contract Research Organizations (CROs). However, the substantial expenses associated with implementing imaging systems and conducting clinical trials stand out as significant obstacles impeding the market's progress.

Market Size Introduction:

The clinical trial imaging market size refers to the total valuation of products and services related to medical imaging utilized in clinical trials worldwide within a specific period, typically a year. It encompasses various imaging modalities, such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and X-ray, used to evaluate the efficacy and safety of investigational drugs and medical devices. Understanding the market size is crucial for stakeholders as it provides insights into the demand for imaging services in clinical research, technological advancements, regulatory landscape, and emerging trends driving market growth. This information serves as a foundation for strategic decision-making, investment planning, and assessing the potential for future expansion within the clinical trial imaging market.

Key Factors:

• Current Valuation
• Historical Growth
• Projected Growth
• Key Drivers
• Segment-wise Analysis

These key factors collectively plays a vital role in shaping the global future for the clinical trial imaging industry.

To know about the assumptions considered for the study download the pdf brochure

• Current Valuation:
  • As of the latest available data, the global clinical trial imaging market size stands at approximately 1.3 USD billion in 2023.
• Historical Growth:
  • Over the past few years, the clinical trial imaging market has experienced steady growth, driven by factors such as increasing pharmaceutical and biotechnology R&D activities, rising prevalence of chronic diseases, and growing demand for imaging-based biomarkers in clinical research.
• Projected Growth:
  • Future growth projections for the clinical trial imaging market remain optimistic, with forecasts indicating a compound annual growth rate (CAGR) of 7.8% over the forecast period of 2023 to 2028.
• Key Drivers:
  • Factors driving the growth of the clinical trial imaging market include advancements in imaging technology, expansion of clinical research activities in emerging markets, regulatory support for imaging-based endpoints in clinical trials, and the growing adoption of precision medicine approaches in drug development.
• Segment-wise Analysis:
  • The clinical trial imaging market comprises various segments, including imaging modalities (MRI, CT, PET, X-ray), imaging services (centralized imaging core labs, site-based imaging services), and therapeutic areas (oncology, neurology, cardiology, etc.). Each segment contributes to the overall market size, with different growth trajectories based on therapeutic needs, technological innovations, and regulatory requirements.

Market Share Introduction:

Market share within the clinical trial imaging industry represents the proportion of total market sales or revenue held by individual companies, imaging modalities, or geographical regions. It serves as a key performance indicator, reflecting the competitive position and relative strength of market players in capturing demand and generating revenues. Analyzing market share data enables stakeholders to assess competitive dynamics, identify market leaders, understand customer preferences, and evaluate the effectiveness of marketing and distribution strategies. Thus, understanding market share is essential for companies to refine their market strategies, optimize resource allocation, and capitalize on growth opportunities within the clinical trial imaging market.

Key Factors:

• Leading Players
• Modality-wise Analysis
• Geographical Distribution
• CROs and Imaging Core Labs
• Therapeutic Area Focus

These key factors collectively plays a vital role in shaping the global future for the clinical trial imaging industry.

• Leading Players:
  • Major players in the clinical trial imaging market include companies such as ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), and Medpace Holdings, Inc. (US) among others, which offer a wide range of imaging services and solutions catering to pharmaceutical sponsors, contract research organizations (CROs), and academic research institutions globally.
• Modality-wise Analysis:
  • Within the clinical trial imaging market, different imaging modalities hold varying market shares. For example, MRI and CT imaging services are commonly used in oncology trials, while PET imaging is prevalent in neurology and cardiology studies, reflecting the therapeutic focus and imaging requirements of different clinical trial programs.
• Geographical Distribution:
  • Geographically, North America, Europe, Asia-Pacific, and other regions represent key markets for clinical trial imaging services. Market share varies across regions based on factors such as healthcare infrastructure, research capabilities, regulatory environment, and clinical trial activity levels.
• CROs and Imaging Core Labs:
  • Contract research organizations (CROs) and imaging core labs play a significant role in the clinical trial imaging market, providing centralized imaging services, image analysis, and regulatory support to sponsors and investigators. Market share among CROs and imaging core labs is influenced by factors such as technical expertise, quality standards, and operational efficiency in delivering imaging services for clinical research studies.
• Therapeutic Area Focus:
  • Market share within the clinical trial imaging industry varies by therapeutic area, with oncology, neurology, and cardiology being among the most prominent areas of clinical research utilizing imaging endpoints. Companies specializing in specific therapeutic areas may have a higher market share within their respective domains, driven by their expertise, experience, and track record in supporting clinical trials in those therapeutic areas.

Related Reports:

Clinical Trial Imaging Market by Software & Service (Operational Imaging, Trial Design), Modality (CT, MRI, X-Ray, PET, Ultrasound, ECHO), Therapeutic Area (Infectious, Oncology, CNS, CVD), End User (Pharma, Biotech, CROs) - Global Forecast to 2028